基于STAIR原则的PSD-95靶向脑细胞保护剂在急性缺血性卒中中的研究进展OA

Brain cytoprotection serves as an important complementary strategy to reperfusion therapy in acute ischemic stroke.To overcome the challenges in the clinical translation of brain cytoprotective agents,the stroke therapy academic industry roundtable(STAIR)was established in 1999 in the United States with the aim of developing a systematic framework to guide drug research and development in stroke.Since its inception,STAIR has continuously refined strategy-specific recommendations for brain cytoprotective agents,providing structured guidance for preclinical experimentation and clinical research.Postsynaptic density protein-95(PSD-95)has emerged as a key target in the brain cytoprotection field owing to its well-defined mechanisms and high target specificity.Under the guidance of STAIR principles,PSD-95-based brain cytoprotective agents have undergone a series of preclinical and clinical studies.This paper systematically reviews the key points of STAIR principles for the development of brain cytoprotective agents and summarizes the status of preclinical and clinical studies of PSD-95-targeting agents under STAIR guidance.It also outlines the research progress on the brain cytoprotective effects of these agents in acute ischemic stroke,thereby providing a reference for the clinical translation of brain cytoprotective agents.